Follow-up and study visits
The design of the study visit schedule and follow-up procedures strongly affects participant burden, adherence and retention in paediatric trials. Visits that are too frequent, too long or too invasive can deter families from enrolling and contribute to dropout. Conversely, insufficient follow-up may compromise data quality and the ability to detect safety signals or changes in outcome measures. A careful balance must be struck between scientific requirements and the practical realities of families’ lives.
Study visit schedule
The frequency and duration of study visits should be determined by the scientific requirements of the protocol and minimized wherever possible. Consideration should be given to:
- combining study visits with routine clinical appointments;
- using telephone or video consultations for safety monitoring visits in which clinical assessment is not required;
- offering flexible scheduling including evenings and weekends; and
- using home visits or mobile research teams for participants who face significant barriers to attending clinic.
The study should also consider whether the investigational medicinal product can be administered at home or only at a trial site. Regulatory bodies may outline specific risk considerations, such as whether it has a well-characterized safety profile, does not require complex preparation or immediate monitoring, is supported by adequate patient supply logistics and has clear protocol instructions.
In addition, the patient and family perspective on visit burden should be sought during protocol development, ideally through formal patient and public involvement consultation. (see Module 1, community engagement and patient and public involvement)
Strategies for retention and adherence
Retention of participants throughout a paediatric trial is essential for data completeness and statistical validity. Key strategies to support participant satisfaction and retention in the study include:
- building strong, trusting relationships between research staff and families;
- providing clear, ongoing communication about the trial and its progress;
- offering practical support such as travel reimbursement, childcare and meal vouchers for clinic visits;
- recognizing and responding promptly to participant and family concerns; and
- using reminder systems (text messages, email and phone calls) to reduce missed visits.
Managing study visits around school and family commitments is a particular challenge in paediatric trials. Scheduling flexibility and collaboration with schools and social services may be needed in long-term trials. Trials should also consult regulatory agencies regarding specific requirements for reimbursement of participants that relate to time, inconvenience and expense compensation.
Sample collection – volume limits and timing
Blood and other biological sample collection in children must be carefully planned to minimise pain, distress and physiological impact. Strict limits on the total volume of blood that can be collected from children of different ages and weights apply in most jurisdictions and must be specified in the protocol (Table 5). As a general guide, the EMA and other regulatory bodies recommend that the trial-related blood loss not exceed 1% of total blood volume at a single time point and a maximum of 3% of total blood volume over a four-week period. Local ethics committee guidance should also be consulted on acceptable blood sampling limits. The timing of pharmacokinetic sampling should be optimized using population pharmacokinetic and sparse sampling approaches to maximize information while minimizing the number of samples required. Clinicians should try and combine pharmacokinetic sampling with safety blood collection to minimize sampling efforts.
Table 5. Recommended paediatric blood volume guidance for research and clinical purposes, estimated by patient weight and patient age
| Patient weight (kg) | Estimated circulating blood volume (mL) | 1% of total blood volume – maximum at a single time (mL) | 3% of total blood volume – maximum over four weeks (mL) |
|---|---|---|---|
| 0.5–1.5 | 50–150 | 0.5–1.5 | 1.5–4.5 |
| 1.5–2.5 | 120–250 | 1.2–2.5 | 3.6–7.5 |
| 2.5–5 | 250–500 | 2.5–5.0 | 7.5–15 |
| 5–12 | 480–960 | 4.8–9.6 | 14.4–28.8 |
| 12–20 | 960–1600 | 9.6–16 | 28.8–48 |
| 20–30 | 1600–2400 | 16–24 | 48–72 |
| 30–50 | 2400–4000 | 24–40 | 72–120 |
| 50–70 | 4000–5600 | 40–56 | 120–168 |
| Patient age (months/years) | Estimated circulating blood volume (mL) | 1% of total blood volume – maximum at a single time (mL) | 3% of total blood volume – maximum over four weeks (mL) |
| Newborn | ~290 | ~2.9 | ~8.6 |
| 3 months | ~535 | ~5.4 | ~16.1 |
| 6 months | ~675 | ~6.7 | ~20.3 |
| 12 months | ~810 | ~8.1 | ~24.2 |
| 6 years | ~1650 | ~16.5 | ~49.4 |
| 12 years | ~3200 | ~32 | ~96 |
| Adolescent | ~4000–5600 | ~40–56 | ~120–168 |
Source for weight estimates: Peplow C, Assfalg R, Beyerlein A, Hasford J, Bonifacio E, Ziegler AG. Blood draws up to 3% of blood volume in clinical trials are safe in children. Acta Paediatr. 2019;108(5):940–944 (https://doi.org/10.1111/apa.14607).
Source for age estimates: Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010;2(4):364–388 (https://doi.org/10.3390/pharmaceutics2040364).
Minimally invasive methods
Minimally invasive or non-invasive sampling methods should be used in preference to conventional venepuncture wherever scientifically valid. Dried blood spot sampling, in which a small volume of capillary blood collected by finger or heel prick is applied to filter paper and dried, is widely used in paediatric pharmacokinetic studies and offers advantages in terms of sample volume, ease of collection and cold-chain requirements. Saliva, urine, stool and breath condensate sampling are appropriate for certain analytes and should be considered where validated. Wearable biosensors and remote monitoring technologies are an emerging area that may further reduce the burden of data collection in paediatric trials.
Sharing study results
Sharing the results of clinical research with participants and their families is both an ethical obligation and good practice. In paediatric trials, results should be communicated in age-appropriate and family-appropriate formats. Plain language summaries, videos and infographics are increasingly used to communicate trial results to lay audiences. The timing of results dissemination should be considered in the protocol, and plans for communicating individual clinically relevant findings should be specified. Special consideration should be given when sharing results with potentially negative consequences, such as with rare or genetic diseases, especially in situations where no treatment or standard of care exists.